Benzothiadiazine dioxide human cytomegalovirus inhibitors: Synthesis and antiviral evaluation of main heterocycle modified derivatives

Antiviral Chemistry and Chemotherapy

Volumn 14, Issue 2, 2003, Pages 107-114

  Martinez, Ana ^a   Gil, Carmen ^a   Castro, Ana ^a   Bruno, Ana M ^a   Pérez, Concepción ^a   Prieto, Columbiana ^b   Otero, Joaquin ^b  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACYCLIC NUCLEOSIDE; BENZOTHIADIAZINE DERIVATIVE; CIDOFOVIR; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; HETEROCYCLIC COMPOUND; QUINAZOLINE DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; BIOAVAILABILITY; CYTOMEGALOVIRUS INFECTION; CYTOTOXICITY; DERIVATIZATION; DRUG SCREENING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; STRAIN DIFFERENCE; STRUCTURE ACTIVITY RELATION; SYNTHESIS; VIRUS INHIBITION; VIRUS REACTIVATION; VIRUS REPLICATION;

EID: 0038464698     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020301400206     Document Type: Article

References (26)

1. Castro A & Martinez A (2000) Novel agents for the treatment of human cytomegalovirus infection. Expert Opinion on Therapeutic Patents 10:165-177.
2. Chou S (1999) Antiviral drug resistance in human cytomegalovirus. Transplant Infectious Disease 1:105-114.
3. Elguero J, Goya P, Martinez A, Rozas I, Mó O, De Paz JLG & Yañez M (1990) Structure of 1,2,6-thiadiazine 1,1-dioxides. Journal of Physical Organic Chemistry 3:470-476.
4. Emery VC (2001) Progress in understanding cytomegalovirus drug resistance. Journal of Clinical Virology 21:223-228.
5. Goya P & Stud M (1978) Synthesis of 4-substituted 3-hydroxy and 3-amino-6H-1,2,6-thiadiazine 1,1-dioxides. Journal of Heterocyclic Chemistry 15:253-256.
6. Griffiths PD (2002) The 2001 Garrod lecture. The treatment of cytomegalovirus infection. Journal of Antimicrobial Chemotherapy 49:243-253.
7. Horvath R, Cerny J, Benedik J Jr, Hold J, Jelinkova I & Benedik J (2000) The possible role of human cytomegalovirus (HCMV) in the origin of atherosclerosis. Journal of Clinical Virology 16:17-24.
8. Levi M (2001) CMV endothelitis as a factor in the pathogenesis of atherosclerosis. Cardiovascular Research 50:432-433.
9. Levin BR, Bull JJ & Stewart FM (2001) Epidemiology, evolution, and future of the HIV/AIDS pandemic. Emerging Infectious Diseases 7:505-511.
10. Limaye AP, Raghu G, Koelle DM, Ferrenberg J, Huang ML & Boeckh M (2002) High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. Journal of Infectious Diseases 185:20-27.
11. Martinez A, Esteban AI & De Clercq E (1997) Benzothiadiazine dioxides acyclonucleosides as lead compounds for the development of new agents against human cytomegalovirus and varicella-zoster virus infections. Bioorganic Medicinal Chemistry Letters 7:1031-1032.
12. Martinez A, Esteban AI, Herrero A, Ochoa C, Andrei G, Snoeck R, Balzarini J & De Clercq E (1999a) Imidazothiadiazine dioxides: synthesis and antiviral activity. Bioorganic Medicinal Chemistry 7:1617-1623.
13. Martinez A, Esteban AI, Castro A, Gil C, Conde S, Andrei G, Snoeck R, Balzarini J & De Clercq E (1999b) Novel potential agents for human cytomegalovirus infection: synthesis and antiviral activity evaluation of benzothiadiazine dioxide acyclonucleosides. Journal of Medicinal Chemistry 42:1145-1150.
14. Martinez A, Gil C, Perez C, Castro A, Prieto C & Otero J (1999c) Chlorophenylmethyl benzothiadiazine dioxides derivatives: potent human cytomegalovirus inhibitors. Bioorganic Medicinal Chemistry Letters 9:3133-3136.
15. Martinez A, Esteban Al, Castro A, Gil C, Andrei G, Snoeck R, Balzarini J & De Clercq E 2000a) Thienothiadiazine 2,2-dioxide acyclonucleosides: synthesis and antiviral activity. Antiviral Chemistry & Chemotherapy 11:221-230.
16. Martinez A, Gil C, Perez C, Castro A, Prieto C, Otero J, Andrei G, Snoeck R, Balzarini J & De Clercq E (2000b) Nonnucleoside human cytomegalovirus inhibitors: synthesis and antiviral evaluation of (chlorophenylmethyl)benzothiadiazine dioxide derivatives. Journal of Medicinal Chemistry 43:3267-3273.
17. Martinez A, Gil C, Abasolo MI, Castro A, Bruno AM, Perez C, Prieto C & Otero J (2000c) Benzothiadiazine dioxide dibenzyl derivatives as potent human cytomegalovirus inhibitors: synthesis and comparative molecular field analysis. Journal of Medicinal Chemistry 43:3218-3225.
18. Martinez A, Castro A, Gil C, Miralpeix M, Segarra V, Domenech T, Beleta J, Palacios JM, Ryder H, Miro X, Bonet C, Casacuberta JM, Azorin F, Piña B & Puigdomenech P (2000d) Benzyl derivatives of 2,1,3-benzo- and benzothieno[3,2-a]thiadiazine 2,2-dioxides: first phosphodiesterase 7 inhibitors. Journal of Medicinal Chemistry. 43:683-689.
19. Martinez A, Castro A, Gil C & Perez C (2001) Recent strategies in the development of new human cytomegalovirus inhibitors. Medicinal Research Reviews 21:227-244.
20. Martinez A, Gil C, Castro A, Perez C, Prieto C & Otero J (2003) Benzothiadiazine dioxides (BTD) derivatives as non-nucleoside human cytomegalovirus (HCMV) inhibitors. Study of structural requirements for biological activity. Bioorganic Medicinal Chemistry, 11:2395-2402.
21. Singh A & Bhandari BM (1976) A new method for the preparation of 1H,3H-quinazoline-2,4-diones and 1H,3H-quinazoline-2-thio-4-ones. Indian Journal of Chemistry, Section B 14:67-68.
22. Snydman DR (2001) Post-transplant microbiological surveillance. Clinical Infectious Diseases 33:S22-S25.
23. Su TL, Bennua B, Vorbrüggen H & Lindner HJ (1981) Nucleoside von 3,6-dihydro-2H-1,2,6-thiadiazin-1,1-dioxiden. Chemische Berichte 114:1269-1278.
24. Van der Bij W & Speich R (2001) Management of cytomegalovirus infection and disease after solid-organ transplantation. Clinical Infectious Diseases 33:S32-S37.
25. Villarreal EC (2001) Current and potential therapies for the treatment of herpesvirus infections. Progress in Drug Research 56:77-120.
26. Wagner G & Rothe L (1969) Synthesis of 2-thioxo-4-oxo-1,2,3,4-tetrahydroquinazolines. Pharmazie 24:513-522.